NOVALIQ ANNOUNCES PUBLICATION OF SECOND PIVOTAL PHASE 3 TRIAL DATA ON CYCLASOL 0.1% (CYCLOSPORINE OPHTHALMIC SOLUTION) IN JAMA OPHTHALMOLOGY
Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol® water-free technology, today announced that results from the second pivotal Phase 3 trial for CyclASol®, ESSENCE-2, have been published in Journal of the American Medical Association (JAMA) Ophthalmology. CyclASol® is currently under regulatory review for the treatment of signs and symptoms of dry eye disease (DED). The U.S. Food and Drug Administration (FDA) has assigned a Prescription Drug User Fee Act (PDUFA) action date of June 8, 2023.